Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Midlife Insulin Resistance as a Predictor for Late-Life Cognitive Function and Cerebrovascular Lesions.

Toppala S, Ekblad LL, Lötjönen J, Helin S, Hurme S, Johansson J, Jula A, Karrasch M, Koikkalainen J, Laine H, Parkkola R, Viitanen M, Rinne JO.

J Alzheimers Dis. 2019 Sep 23. doi: 10.3233/JAD-190691. [Epub ahead of print]

PMID:
31561373
2.

Effects of age, BMI and sex on the glial cell marker TSPO - a multicentre [11C]PBR28 HRRT PET study.

Tuisku J, Plavén-Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Brück A, Carson RE, Chen MK, Cosgrove KP, Ekblad L, Esterlis I, Farde L, Forsberg A, Halldin C, Helin S, Kosek E, Lekander M, Lindgren N, Marjamäki P, Rissanen E, Sucksdorff M, Varrone A; HRRT [11C ]PBR28 study group, Collste K, Gallezot JD, Hillmer A, Huang Y, Höglund CO, Johansson J, Jucaite A, Lampa J, Nabulsi N, Pittman B, Sandiego CM, Stenkrona P, Rinne J, Matuskey D, Cervenka S.

Eur J Nucl Med Mol Imaging. 2019 Oct;46(11):2329-2338. doi: 10.1007/s00259-019-04403-7. Epub 2019 Jul 30.

3.

68Ga-DOTA chelate, a novel imaging agent for assessment of myocardial perfusion and infarction detection in a rodent model.

Autio A, Uotila S, Kiugel M, Kytö V, Liljenbäck H, Kudomi N, Oikonen V, Metsälä O, Helin S, Knuuti J, Saraste A, Roivainen A.

J Nucl Cardiol. 2019 May 29. doi: 10.1007/s12350-019-01752-6. [Epub ahead of print]

PMID:
31144229
4.

Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects.

Johansson J, Hirvonen J, Lovró Z, Ekblad L, Kaasinen V, Rajasilta O, Helin S, Tuisku J, Sirén S, Pennanen M, Agrawal A, Crystal R, Vainio PJ, Alho H, Scheinin M.

Neuropsychopharmacology. 2019 Aug;44(9):1667-1673. doi: 10.1038/s41386-019-0368-x. Epub 2019 Mar 13.

PMID:
30867551
5.

Brain β-Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline.

Martikainen IK, Kemppainen N, Johansson J, Teuho J, Helin S, Liu Y, Helisalmi S, Soininen H, Parkkola R, Ngandu T, Kivipelto M, Rinne JO.

AJNR Am J Neuroradiol. 2019 Jan;40(1):80-85. doi: 10.3174/ajnr.A5891. Epub 2018 Dec 13.

PMID:
30545837
6.

Correction to: Regulation of human brown adipose tissue by adenosine and A2A receptors - studies with [15O]H2O and [11C]TMSX PET/CT.

Lahesmaa M, Oikonen V, Helin S, Luoto P, U Din M, Pfeifer A, Nuutila P, Virtanen KA.

Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2244. doi: 10.1007/s00259-018-4144-7.

PMID:
30196366
7.

Regulation of human brown adipose tissue by adenosine and A2A receptors - studies with [15O]H2O and [11C]TMSX PET/CT.

Lahesmaa M, Oikonen V, Helin S, Luoto P, U Din M, Pfeifer A, Nuutila P, Virtanen KA.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):743-750. doi: 10.1007/s00259-018-4120-2. Epub 2018 Aug 13. Erratum in: Eur J Nucl Med Mol Imaging. 2018 Nov;45(12):2244.

8.

S-[18F]THK-5117-PET and [11C]PIB-PET Imaging in Idiopathic Normal Pressure Hydrocephalus in Relation to Confirmed Amyloid-β Plaques and Tau in Brain Biopsies.

Leinonen V, Rauramaa T, Johansson J, Bottelbergs A, Tesseur I, van der Ark P, Pemberton D, Koivisto AM, Jääskeläinen JE, Hiltunen M, Herukka SK, Blennow K, Zetterberg H, Jokinen P, Rokka J, Helin S, Haaparanta-Solin M, Solin O, Okamura N, Kolb HC, Rinne JO.

J Alzheimers Dis. 2018;64(1):171-179. doi: 10.3233/JAD-180071.

PMID:
29865068
9.

Binge eating disorder and morbid obesity are associated with lowered mu-opioid receptor availability in the brain.

Joutsa J, Karlsson HK, Majuri J, Nuutila P, Helin S, Kaasinen V, Nummenmaa L.

Psychiatry Res Neuroimaging. 2018 Jun 30;276:41-45. doi: 10.1016/j.pscychresns.2018.03.006. Epub 2018 Mar 9.

PMID:
29655552
10.

Midlife insulin resistance, APOE genotype, and late-life brain amyloid accumulation.

Ekblad LL, Johansson J, Helin S, Viitanen M, Laine H, Puukka P, Jula A, Rinne JO.

Neurology. 2018 Mar 27;90(13):e1150-e1157. doi: 10.1212/WNL.0000000000005214. Epub 2018 Feb 23.

11.

Neuroinflammation Appears Early on PET Imaging and Then Plateaus in a Mouse Model of Alzheimer Disease.

López-Picón FR, Snellman A, Eskola O, Helin S, Solin O, Haaparanta-Solin M, Rinne JO.

J Nucl Med. 2018 Mar;59(3):509-515. doi: 10.2967/jnumed.117.197608. Epub 2017 Oct 6.

12.

Brain glucose metabolism and its relation to amyloid load in middle-aged adults with childhood-onset epilepsy.

Joutsa J, Rinne JO, Karrasch M, Hermann B, Johansson J, Anttinen A, Eskola O, Helin S, Shinnar S, Sillanpää M; TACOE study group.

Epilepsy Res. 2017 Nov;137:69-72. doi: 10.1016/j.eplepsyres.2017.09.006. Epub 2017 Sep 20.

PMID:
28950220
13.

Feeding Releases Endogenous Opioids in Humans.

Tuulari JJ, Tuominen L, de Boer FE, Hirvonen J, Helin S, Nuutila P, Nummenmaa L.

J Neurosci. 2017 Aug 23;37(34):8284-8291. doi: 10.1523/JNEUROSCI.0976-17.2017. Epub 2017 Jul 26.

14.

Applicability of [11C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model.

Snellman A, Rokka J, López-Picón FR, Helin S, Re F, Löyttyniemi E, Pihlaja R, Forloni G, Salmona M, Masserini M, Solin O, Rinne JO, Haaparanta-Solin M.

Neurobiol Aging. 2017 Sep;57:84-94. doi: 10.1016/j.neurobiolaging.2017.05.008. Epub 2017 May 15.

15.

Neurotransmitters behind pain relief with transcranial magnetic stimulation - positron emission tomography evidence for release of endogenous opioids.

Lamusuo S, Hirvonen J, Lindholm P, Martikainen IK, Hagelberg N, Parkkola R, Taiminen T, Hietala J, Helin S, Virtanen A, Pertovaara A, Jääskeläinen SK.

Eur J Pain. 2017 Oct;21(9):1505-1515. doi: 10.1002/ejp.1052. Epub 2017 May 11.

PMID:
28493519
16.

Bariatric surgery normalizes brain opioid receptors.

Karlsson HK, Tuulari JJ, Tuominen L, Hirvonen J, Honka H, Parkkola R, Helin S, Salminen P, Nuutila P, Nummenmaa L.

Mol Psychiatry. 2016 Aug;21(8):989. doi: 10.1038/mp.2016.116. No abstract available.

PMID:
27439757
17.

Weight loss after bariatric surgery normalizes brain opioid receptors in morbid obesity.

Karlsson HK, Tuulari JJ, Tuominen L, Hirvonen J, Honka H, Parkkola R, Helin S, Salminen P, Nuutila P, Nummenmaa L.

Mol Psychiatry. 2016 Aug;21(8):1057-62. doi: 10.1038/mp.2015.153. Epub 2015 Oct 13.

PMID:
26460230
18.

Aberrant mesolimbic dopamine-opiate interaction in obesity.

Tuominen L, Tuulari J, Karlsson H, Hirvonen J, Helin S, Salminen P, Parkkola R, Hietala J, Nuutila P, Nummenmaa L.

Neuroimage. 2015 Nov 15;122:80-6. doi: 10.1016/j.neuroimage.2015.08.001. Epub 2015 Aug 7.

PMID:
26260431
19.

Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease.

Jucaite A, Svenningsson P, Rinne JO, Cselényi Z, Varnäs K, Johnström P, Amini N, Kirjavainen A, Helin S, Minkwitz M, Kugler AR, Posener JA, Budd S, Halldin C, Varrone A, Farde L.

Brain. 2015 Sep;138(Pt 9):2687-700. doi: 10.1093/brain/awv184. Epub 2015 Jul 1.

PMID:
26137956
20.

Obesity is associated with decreased μ-opioid but unaltered dopamine D2 receptor availability in the brain.

Karlsson HK, Tuominen L, Tuulari JJ, Hirvonen J, Parkkola R, Helin S, Salminen P, Nuutila P, Nummenmaa L.

J Neurosci. 2015 Mar 4;35(9):3959-65. doi: 10.1523/JNEUROSCI.4744-14.2015.

21.

Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain.

Lehto J, Virta JR, Oikonen V, Roivainen A, Luoto P, Arponen E, Helin S, Hietamäki J, Holopainen A, Kailajärvi M, Peltonen JM, Rouru J, Sallinen J, Virtanen K, Volanen I, Scheinin M, Rinne JO.

Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):120-7. doi: 10.1007/s00259-014-2899-z. Epub 2014 Sep 9.

PMID:
25201008
22.

Dimeric [(68)Ga]DOTA-RGD peptide targeting αvβ 3 integrin reveals extracellular matrix alterations after myocardial infarction.

Kiugel M, Dijkgraaf I, Kytö V, Helin S, Liljenbäck H, Saanijoki T, Yim CB, Oikonen V, Saukko P, Knuuti J, Roivainen A, Saraste A.

Mol Imaging Biol. 2014 Dec;16(6):793-801. doi: 10.1007/s11307-014-0752-1.

PMID:
24984688
23.

¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men.

Luoto P, Suilamo S, Oikonen V, Arponen E, Helin S, Herttuainen J, Hietamäki J, Holopainen A, Kailajärvi M, Peltonen JM, Rouru J, Sallinen J, Scheinin M, Virta J, Virtanen K, Volanen I, Roivainen A, Rinne JO.

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1947-56. doi: 10.1007/s00259-014-2782-y. Epub 2014 May 17.

PMID:
24838249
24.

A PET Tracer for Brain α2C Adrenoceptors, (11)C-ORM-13070: Radiosynthesis and Preclinical Evaluation in Rats and Knockout Mice.

Arponen E, Helin S, Marjamäki P, Grönroos T, Holm P, Löyttyniemi E, Någren K, Scheinin M, Haaparanta-Solin M, Sallinen J, Solin O.

J Nucl Med. 2014 Jul;55(7):1171-7. doi: 10.2967/jnumed.113.135574. Epub 2014 May 5.

25.

6-[18F]fluoro-L-DOPA uptake in the rat pancreas is dependent on the tracer metabolism.

Kalliokoski T, Tuomela J, Haavisto L, Forsback S, Snellman A, Helin S, Grönroos TJ, Solin O, Haaparanta-Solin M.

Mol Imaging Biol. 2014 Jun;16(3):403-11. doi: 10.1007/s11307-013-0701-4. Epub 2013 Nov 12.

PMID:
24217945
26.

[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment.

Brück A, Virta JR, Koivunen J, Koikkalainen J, Scheinin NM, Helenius H, Någren K, Helin S, Parkkola R, Viitanen M, Rinne JO.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1567-72. doi: 10.1007/s00259-013-2478-8. Epub 2013 Jun 26.

PMID:
23801168
27.

Adenosine A2A receptors in secondary progressive multiple sclerosis: a [(11)C]TMSX brain PET study.

Rissanen E, Virta JR, Paavilainen T, Tuisku J, Helin S, Luoto P, Parkkola R, Rinne JO, Airas L.

J Cereb Blood Flow Metab. 2013 Sep;33(9):1394-401. doi: 10.1038/jcbfm.2013.85. Epub 2013 May 22.

28.

Serotonin transporter in attention-deficit hyperactivity disorder--preliminary results from a positron emission tomography study.

Karlsson L, Tuominen L, Huotarinen A, Leppämäki S, Sihvola E, Helin S, Sipilä M, Tani P, Hirvonen J, Hietala J, Karlsson H.

Psychiatry Res. 2013 May 30;212(2):164-5. doi: 10.1016/j.pscychresns.2013.02.001. Epub 2013 Apr 6.

PMID:
23566552
29.

Cognitive decline and amyloid accumulation in patients with mild cognitive impairment.

Koivunen J, Karrasch M, Scheinin NM, Aalto S, Vahlberg T, Någren K, Helin S, Viitanen M, Rinne JO.

Dement Geriatr Cogn Disord. 2012;34(1):31-7. doi: 10.1159/000341580. Epub 2012 Aug 3.

PMID:
22868352
30.

Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Någren K, Helin S, Parkkola R, Viitanen M, Rinne JO.

Neurology. 2011 Mar 22;76(12):1085-90. doi: 10.1212/WNL.0b013e318212015e. Epub 2011 Feb 16.

PMID:
21325653
31.

Gender differences in brain serotonin transporter availability in panic disorder.

Maron E, Tõru I, Hirvonen J, Tuominen L, Lumme V, Vasar V, Shlik J, Nutt DJ, Helin S, Någren K, Tiihonen J, Hietala J.

J Psychopharmacol. 2011 Jul;25(7):952-9. doi: 10.1177/0269881110389207. Epub 2010 Dec 8.

PMID:
21148024
32.

Human biodistribution and radiation dosimetry of 11C-(R)-PK11195, the prototypic PET ligand to image inflammation.

Hirvonen J, Roivainen A, Virta J, Helin S, Någren K, Rinne JO.

Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):606-12. doi: 10.1007/s00259-009-1298-3. Epub 2009 Oct 28.

PMID:
19862517
33.

Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.

Scheinin NM, Aalto S, Koikkalainen J, Lötjönen J, Karrasch M, Kemppainen N, Viitanen M, Någren K, Helin S, Scheinin M, Rinne JO.

Neurology. 2009 Oct 13;73(15):1186-92. doi: 10.1212/WNL.0b013e3181bacf1b. Epub 2009 Sep 2.

PMID:
19726751
34.

Effects of intravenous placebo with glucose expectation on human basal ganglia dopaminergic function.

Haltia LT, Rinne JO, Helin S, Parkkola R, Någren K, Kaasinen V.

Synapse. 2008 Sep;62(9):682-8. doi: 10.1002/syn.20541.

PMID:
18566972
35.

Amino-acid-based peritoneal dialysis solution improves amino-acid transport into skeletal muscle.

Asola M, Virtanen K, Någren K, Helin S, Taittonen M, Kastarinen H, Anderstam B, Knuuti J, Metsärinne K, Nuutila P.

Kidney Int Suppl. 2008 Apr;(108):S131-6. doi: 10.1038/sj.ki.5002614.

36.

Effects of intravenous glucose on dopaminergic function in the human brain in vivo.

Haltia LT, Rinne JO, Merisaari H, Maguire RP, Savontaus E, Helin S, Någren K, Kaasinen V.

Synapse. 2007 Sep;61(9):748-56.

PMID:
17568412
37.

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO.

Neurology. 2007 May 8;68(19):1603-6.

PMID:
17485647
38.

Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease.

Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO.

Neurology. 2006 Nov 14;67(9):1575-80. Epub 2006 Sep 13.

PMID:
16971697
39.

Structural basis for the activity of two muconate cycloisomerase variants toward substituted muconates.

Schell U, Helin S, Kajander T, Schlömann M, Goldman A.

Proteins. 1999 Jan 1;34(1):125-36.

PMID:
10336378
40.

Socio-economic status, health and life-style in two elderly cohorts in Jyväskylä.

Pohjolainen P, Heikkinen E, Lyyra AL, Helin S, Tyrkkö K.

Scand J Soc Med Suppl. 1997;52:1-65. No abstract available.

PMID:
9241696
41.

Crystallization and preliminary crystallographic analysis of 3-carboxy-cis,cis-muconate lactonizing enzyme from Neurospora crassa.

Glumoff T, Helin S, Mazur P, Kozarich JW, Goldman A.

Acta Crystallogr D Biol Crystallogr. 1996 Jan 1;52(Pt 1):221-3.

PMID:
15299752
42.

The refined X-ray structure of muconate lactonizing enzyme from Pseudomonas putida PRS2000 at 1.85 A resolution.

Helin S, Kahn PC, Guha BL, Mallows DG, Goldman A.

J Mol Biol. 1995 Dec 15;254(5):918-41.

PMID:
7500361

Supplemental Content

Support Center